INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indivior Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$33.87+1.42 (+4.38%)
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Indivior Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $4.00B | $166.30M |
| Enterprise Value | $4.26B | $88.19M |
| PE Ratio | 12.18 | 20.44 |
| PS Ratio | 3.00 | 3.65 |
Enterprise value
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 3.20 | 2.51 |
| EV / EBITDA | 9.91 | 14.65 |
| EV / EBIT | 10.12 | 19.00 |
Income (trailing twelve months)
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $1.33B | $58.34M |
| Gross Profit | $1.09B | $105.94M |
| Operating Income | $421.00M | -$21.40M |
| Pretax Income | $393.00M | -$14.34M |
| Net Income | $355.00M | -$22.46M |
| EBITDA | $430.00M | -$16.91M |
| EPS (Diluted) | $2.78 | -$0.83 |
Margins
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 82.1% | 52.9% |
| Operating Margin | 31.6% | -44.0% |
| Pretax Margin | 29.5% | -13.3% |
| Profit Margin | 26.7% | -40.2% |
| EBITDA Margin | 32.3% | -30.2% |
| FCF Margin | -8.33% | -9.27% |
Returns
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | 26.4% | -40.9% |
| Return on Capital Employed (ROCE) | 115.3% | -38.1% |
Growth
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 13.5% | 5.96% |
| Net Income Growth (YoY) | 228.7% | -35.2% |
| EPS Growth (YoY) | 231.0% | -26.2% |
| FCF Growth (YoY) | -164.2% | 2.34% |
| Revenue Growth (3Y CAGR) | 11.2% | 2.25% |
Balance sheet
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $222.00M | $61.43M |
| Total Debt | $487.00M | $118.52M |
| Net Cash (Debt) | -$265.00M | $15.35M |
| Net Cash Per Share | -$2.25 | $0.66 |
| Equity (Book Value) | -$208.00M | $49.09M |
| Book Value Per Share | -$1.76 | $1.37 |
| Tangible Book Value | -$208.00M | $23.52M |
| Working Capital | -$143.00M | $76.81M |
Financial position
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.84 | 3.34 |
| Quick Ratio | 0.57 | 2.44 |
| Debt / EBITDA | 1.13 | 3.44 |
| Net Debt / EBITDA | 0.62 | 2.36 |
| Interest Coverage | 15.59 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$40.00M | -$12.35M |
| Capital Expenditures | -$71.00M | -$1.08M |
| Free Cash Flow | -$111.00M | -$20.22M |
| FCF Per Share | -$0.94 | -$0.42 |
Efficiency
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.99 | 0.39 |
| Inventory Turnover | 1.61 | 2.70 |
| Revenue Per Employee | $1.59M | $404.87K |
| Profits Per Employee | $423.63K | -$703.34K |
| Employee Count | 838 | 74 |
Dividends and yields
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 8.88% | -23.3% |
| FCF Yield | -2.78% | -8.72% |
| Buyback Yield | 7.53% | -0.59% |
| Shareholder Yield | 7.53% | 0.00% |
Shares
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 118,014,000 | 58,127,000 |
| Shares Change (YoY) | -0.19% | 10.9% |
| Float | 102,225,000 | 49,136,700 |
| Shares Held by Insiders | 13.4% | 11.6% |
| Shares Held by Institutions | 104.2% | 59.4% |
Taxes
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $38.00M | $79.87K |
| Effective Tax Rate | 9.67% | 20.6% |
Scores
| Measure | Indivior Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 3.35 | -0.22 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -1.39 | -2.62 |
Calculated by StockData from Indivior Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.